News Content
**Core Effect: Precisely blocking DHT production** is the starting point for all these changes. It inhibits 5α-reductase activity by approximately 70%-80%, significantly reducing DHT levels in serum and tissues-a crucial issue for patients with male pattern baldness (androgenic alopecia). Scalp hair follicles are sensitive to DHT, and reduced DHT levels allow atrophied follicles to gradually regain activity. Clinical data show that taking 1 mg daily for 6-12 months increases hair density in approximately 65% of patients, with new, fine hair appearing in areas of hair loss. Furthermore, DHT reduction can reduce the size of enlarged prostates and alleviate urinary difficulties caused by benign prostatic hyperplasia. After 12 months of use, prostate volume shrinks by an average of 20%-30%, and urine flow rate increases by 15%-20%.https://www.fiercerawsource.com/steroid-finished/steroid-finished-tablets/stromusc-pills-5mg-finasteride-100-tablets.html
**Hidden Effects: Non-Ignoreable Systemic Fluctuations** Often overlooked. Some male users experience reproductive system effects such as decreased libido and erectile dysfunction, with an incidence of approximately 2%-4%. These effects typically occur in the early stages of treatment, and most people gradually tolerate them. A minority experience mood changes, such as anxiety and depression, which are related to interference with DHT's regulatory effects on neurotransmitters such as dopamine. Metabolically, long-term use may lead to a slight increase in testosterone levels (usually within the normal range), but this has no significant impact on blood lipids, blood sugar, and other indicators. There is no need to overly worry about "hormone imbalance leading to metabolic disorders."
**Individual Differences: Responses and Effects Can Vary Significantly** Among patients with hair loss, the frontal hairline generally responds less well to medication than the vertex. Approximately 30% of patients experience only maintenance of existing hair volume without significant regrowth. For patients with benign prostatic hyperplasia (BPH), if the gland volume exceeds 80ml, the drug's effectiveness may be limited and other treatments may be necessary. Urology experts emphasize that "finasteride is a 'targeted modulator,' not a 'cure-all.' Its effects and risks are directly related to the physiological effects of DHT. Pre-treatment testing is essential to confirm the indication and regular monitoring of the body's response during use to strike a balance between benefit and safety."
